性早熟是脊柱侧凸的重要风险因素:GnRHa治疗协同效应与维生素D保护作用的回顾性队列研究
该研究通过横断面(5605人)和回顾性队列(1575人)分析发现,性早熟患者脊柱侧凸患病率显著高于对照组(19.2% vs. 5.6%,P<0.001),调整OR为3.92;队列中性早熟使新发脊柱侧凸风险升高5.44倍。GnRHa治疗独立增加风险(HR=1.99,P=0.004),而维生素D补充使GnRHa治疗患者侧凸发生率降低51.5%(HR=0.43,P<0.001)。
要点
- 性早熟患者脊柱侧凸患病率19.2%,显著高于对照组的5.6%。
- GnRHa治疗独立增加脊柱侧凸风险(HR=1.99,P=0.004)。
- 维生素D补充使GnRHa治疗患者侧凸发生率降低51.5%。
核心结论
- 性早熟与GnRHa治疗协同增加脊柱侧凸风险,而维生素D联合治疗可减轻此效应。
- 建议对开始GnRHa治疗的性早熟患者进行基线脊柱监测并补充维生素D。
研究设计与样本
- 横断面分析纳入5605名参与者,回顾性队列纳入1575名个体。
- 从医疗记录获取性早熟诊断、GnRHa治疗和维生素D补充数据。
- 脊柱侧凸放射学定义为Cobb角≥10°。
- 横断面分析采用Logistic回归,队列分析采用Cox回归评估关联。
主要发现
- 横断面研究中,性早熟组脊柱侧凸患病率为19.2%,对照组为5.6%(P<0.001),调整OR为3.92。
- 维生素D缺乏进一步增加脊柱侧凸风险(HR=2.04,P=0.003)。
- 纵向队列中,性早熟与新发脊柱侧凸风险升高5.44倍相关。
- GnRHa治疗独立增加脊柱侧凸风险(HR=1.99,P=0.004)。
- 维生素D补充使GnRHa治疗患者脊柱侧凸发生率降低51.5%(HR=0.43,P<0.001)。
关键数值与推荐
- 脊柱侧凸放射学定义:Cobb角≥10°。
- 性早熟组脊柱侧凸患病率19.2%,对照组5.6%(P<0.001),调整OR=3.92。
- 维生素D缺乏增加脊柱侧凸风险HR=2.04(P=0.003)。
- 性早熟与新发脊柱侧凸风险HR=5.44。
- GnRHa治疗增加脊柱侧凸风险HR=1.99(P=0.004)。
临床怎么用
- 对性早熟患者应进行基线脊柱监测。
- 对开始GnRHa治疗的患者建议补充维生素D。
- 关注维生素D缺乏的性早熟患者脊柱侧凸风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: Cross-sectional and retrospective cohort study. OBJECTIVE: This study aimed to investigate the impact of precocious puberty (PP) on scoliosis development and to evaluate the effects of gonadotropin-releasing hormone agonist (GnRHa) therapy and vitamin D (VitD) supplementation. SUMMARY OF BACKGROUND DATA: The effects of precocious puberty, GnRHa therapy, and VitD supplementation on scoliosis remain unclear. METHODS: The cross-sectional analysis included 5605 participants, while the retrospective cohort comprised 1575 individuals. Data on PP diagnosis, GnRHa therapy, VitD supplementation were obtained from medical records. Scoliosis was radiographically defined as a Cobb angle ≥10°. Logistic and Cox regression models were used in cross-sectional and cohort analyses, respectively, to assess the associations of PP and GnRHa therapy with scoliosis incidence. RESULTS: In the cross-sectional study, scoliosis prevalence was higher in the PP group compared with controls (19.2% vs. 5.6%, P <0.001), yielding an adjusted odds ratio (OR) of 3.92. Vitamin D deficiency further increased scoliosis risk (HR=2.04, P =0.003). In the longitudinal cohort, PP was associated with a 5.44-fold elevated risk of de novo scoliosis. GnRHa therapy independently increased scoliosis risk (HR=1.99, P =0.004). Conversely, VitD supplementation reduced scoliosis incidence by 51.5% among GnRHa-treated patients (HR=0.43, P <0.001). A U-shaped biphasic association was observed between estradiol levels and scoliosis risk (non-linear P <0.05). CONCLUSION: PP and GnRHa therapy synergistically increase scoliosis risk, whereas VitD co-therapy mitigates this effect. Baseline spinal surveillance and VitD supplementation are recommended for PP patients initiating GnRHa therapy. LEVEL OF EVIDENCE: 3.
引用
- Zhang S, Li X, Wu Y, et al. Precocious Puberty as a Significant Risk Factor for Scoliosis: A Retrospective Cohort Study Demonstrating Synergistic Effects of GnRHa Therapy and Protective Role of Vitamin D. Spine (Phila Pa 1976). 2026. PMID: 41944804. doi:10.1097/BRS.0000000000005681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。